XML Persian Abstract Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

teimourpour R, mohammadshahi J, arzanlou M, habibzadeh S, peeridogaheh H. Three-Year Trend of Antimicrobial Resistance of A. baumannii: A Retrospective Study from Ardabil, Northwestern Iran. Journal of Research in Applied and Basic Medical Sciences 2020; 6 (3) :186-193
URL: http://ijrabms.umsu.ac.ir/article-1-131-en.html
Department of Infectious Diseases and Tropical Medicine, School of Medicine, Ardabil University of Medical Sciences, Ardabil, Iran , r.teymourpour@gmail.com
Abstract:   (1412 Views)
Background & Aims:  Acinetobacter baumannii is one of the most important pathogenic bacteria causing nosocomial and opportunistic infection with the high rate of antibiotic resistance. The aim of the present work was to study the antimicrobial resistance pattern of Acinetobacter isolates recovered from patients admitted to Imam Khomeini Hospital and identifying the related risk factors. Also, in this study, the efficacy of different combined antimicrobial therapy against A. baumannii was evaluated.
Materials & Methods: In this retrospective study, a total of 108 medical records related to patients admitted to Imam Khomeini Hospital in Ardabil province from 2011 to 2013 was entered into the study. For each patient, demographic, bacterial culture, and antibiogram data were obtained and analyzed.
Results: Results indicated that pulmonary infections were the most common clinical source of Acinetobacter infection. The highest rate of resistance (100%) was related to ceftizoxime, chloramphenicol, furazolidone, nitrofurantoin, cephalothin, cephalexin, ticarcillin, piperacillin, amoxicillin, and aztreonam followed by ceftazidime, imipenem, co-trimoxazole, ceftriaxone, cefotaxime, and cefixime (80%). The lowest rate of resistance was seen against polymyxin B, ampicillin/sulbactam and meropenem. Our results indicated that 86.9 % and 91.7% of isolates were resistant to ceftriaxone and imipenem, respectively. Since carbapenems are the drug of choice and the last-resort agent for the treatment of MDR strain of A. baumannii , this high resistance level would be a serious concern.
Conclusion: The epidemiological survey will be helpful in controlling infections in hospital environment and prescribing proper antimicrobial agents.
Full-Text [PDF 707 kb]   (955 Downloads)    
Type of Study: orginal article | Subject: General

1. Bennett JE, Dolin R, Blaser MJ. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases: 2-Volume Set. Elsevier Health Sciences; 2014. [Google Book]
2. Wang X, Qin L-J. A review on Acinetobacter baumannii. Journal of Acute Disease 2019;8(1):16-20. [DOI:10.4103/2221-6189.250373]
3. Ballouz T, Aridi J, Afif C, Irani J, Lakis C, Nasreddine R, et al. Risk factors, clinical presentation, and outcome of Acinetobacter baumannii bacteremia. Front Cell Infect Microbiol 2017;7:156. [DOI:10.3389/fcimb.2017.00156]
4. Ellis D, Cohen B, Liu J, Larson E. Risk factors for hospital-acquired antimicrobial-resistant infection caused by Acinetobacter baumannii. Antimicrob Resist Infect Control 2015;4(1):40. [DOI:10.1186/s13756-015-0083-2]
5. Navidinia M, Goudarzi M, Rameshe SM, Farajollahi Z, Asl PE, Mounesi MR. Molecular characterization of resistance genes in MDR-ESKAPE pathogens. J Pure Appl Microbiol 2017;11(2):779-93. [DOI:10.22207/JPAM.11.2.17]
6. Lee C-R, Lee JH, Park M, Park KS, Bae IK, Kim YB, et al. Biology of Acinetobacter baumannii: pathogenesis, antibiotic resistance mechanisms, and prospective treatment options. Front Cell Infect Microbiol 2017;7:55. [DOI:10.3389/fcimb.2017.00055]
7. Nowak P, Paluchowska P. Acinetobacter baumannii: biology and drug resistance-role of carbapenemases. Folia Histochem Cytobiol 2016;54(2):61-74. [DOI:10.5603/FHC.a2016.0009]
8. Antunes L, Visca P, Towner KJ. Acinetobacter baumannii: evolution of a global pathogen. Foodborne Pathog Dis 2014;71(3):292-301. [DOI:10.1111/2049-632X.12125]
9. Almaghrabi MK, Joseph MR, Assiry MM, Hamid ME. Multidrug-resistant Acinetobacter baumannii: an emerging health threat in Aseer Region, Kingdom of Saudi Arabia. Can J Infect Dis Med Microbiol 2018;2018: 9182747. [DOI:10.1155/2018/9182747]
10. Nor FM, Shahari A, Palaniasamy N, Rustam FM, M-Zain Z, Lee B, et al. Multidrug resistant (MDR) Acinetobacter baumannii: rate of occurrence from a tertiary hospital, Malaysia. Int J Infect Dis 2019;79:46-7. [DOI:10.1016/j.ijid.2018.11.126]
11. Kanafani Z, Kanj S. Acinetobacter infection: Treatment and prevention. 2015.
12. Kanafani ZA, Zahreddine N, Tayyar R, Sfeir J, Araj GF, Matar GM, et al. Multi-drug resistant Acinetobacter species: a seven-year experience from a tertiary care center in Lebanon. Antimicrob Resist Infect Control 2018;7(1):9. [DOI:10.1186/s13756-017-0297-6]
13. Teerawattanapong N, Panich P, Kulpokin D, Ranong SN, Kongpakwattana K, Saksinanon A, et al. A systematic review of the burden of multidrug-resistant healthcare-associated infections among intensive care unit patients in Southeast Asia: the rise of multidrug-resistant Acinetobacter baumannii. Infect Control Hosp Epidemiol 2018;39(5):525-33. [DOI:10.1017/ice.2018.58]
14. Tacconelli E, Carrara E, Savoldi A, Harbarth S, Mendelson M, Monnet DL, et al. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect Dis 2018;18(3):318-27. [DOI:10.1016/S1473-3099(17)30753-3]
15. Koulenti D, Lisboa T, Brun-Buisson C, Krueger W, Macor A, Sole-Violan J, et al. Spectrum of practice in the diagnosis of nosocomial pneumonia in patients requiring mechanical ventilation in European intensive care units. Crit Care Med 2009;37(8):2360-9. [DOI:10.1097/CCM.0b013e3181a037ac]
16. Tjoa E, Moehario LH, Rukmana A, Rohsiswatmo R. Acinetobacter baumannii: role in blood stream infection in neonatal unit, Dr. Cipto Mangunkusumo Hospital, Jakarta, Indonesia. Int J Microbiol 2013;2013:180763. [DOI:10.1155/2013/180763]
17. Rebic V, Masic N, Teskeredzic S, Aljicevic M, Abduzaimovic A, Rebic D. The Importance of Acinetobacter Species in the Hospital Environment. Med Arch 2018;72(5):325. [DOI:10.5455/medarh.2018.72.330-334]
18. Garnacho-Montero J, Timsit J-F. Managing Acinetobacter baumannii infections. Curr Opin Infect Dis 2019;32(1):69-76. [DOI:10.1097/QCO.0000000000000518]

Add your comments about this article : Your username or Email:

Send email to the article author

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2023 CC BY-NC 4.0 | Journal of Research in Applied and Basic Medical Sciences

Designed & Developed by : Yektaweb